Although current osteoporosis therapies are effective in reducing the risk of fracture and increasing bone mineral density, all have some issues that limit their use. The GI side effects of oral bisphosphonates may preclude their use in some patients, while agents requiring intravenous or subcutaneous administration may pose problems with compliance for others. Recent advances in understanding bone remodeling and the pathophysiology of osteoporosis have led to the identification of novel therapeutic targets and the development of new emerging agents. Three experts in the field – Dolores M. Shoback, MD, Paul D. Miller, MD, and E. Michael Lewiecki, MD – discuss these important advances and their implications for the treatment of patients at risk of fracture and bone loss.
E. Michael Lewiecki, MD, FACP, FACE
- Osteoporosis Director
- New Mexico Clinical Research & Osteoporosis Center
- Clinical Assistant Professor of Medicine
- University of New Mexico School of Medicine
- Albuquerque, New Mexico
Paul D. Miller, MD
- Distinguished Clinical Professor of Medicine
- University of Colorado Medical Center
- Colorado Center for Bone Research
- Lakewood, Colorado
Dolores M. Shoback, MD
- Professor of Medicine
- Department of Medicine
- University of California
- San Francisco VA Medical Center
- San Francisco, California
Paul D. Miller, MD, has received grant/research support from Amgen Inc, Eli Lilly and Company, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis; and is a consultant for and/or on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, NPS Pharmaceuticals Inc, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis. Dr. Miller will be discussing the off-label/investigational uses of clodronate, etidronate, pamidronate, and strontium ranelate.
Dolores M. Shoback, MD, is a consultant for Amgen Inc, and GlaxoSmithKline; and has received honoraria from GlaxoSmithKline and Kai Pharmaceuticals. Dr. Shoback will be discussing the off-label/investigational use of sclerostin monoclonal antibody.
Paul D. Miller, MD, has received grant/research support from Amgen Inc, Eli Lilly and Company, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis; and is a consultant for and/or on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, NPS Pharmaceuticals Inc, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis. Dr. Miller will be discussing the off-label/investigational uses of clodronate, etidronate, pamidronate, and strontium ranelate.
Dolores M. Shoback, MD, is a consultant for Amgen Inc, and GlaxoSmithKline; and has received honoraria from GlaxoSmithKline and Kai Pharmaceuticals. Dr. Shoback will be discussing the off-label/investigational use of sclerostin monoclonal antibody.
Available for CME/CE:
Physicians
Publish Date: Nov 10, 2009 Termination Date: Nov 10, 2010Nurses
Publish Date: Nov 10, 2009 Termination Date: Nov 10, 2010Pharmacists
Publish Date: Nov 10, 2009 Termination Date: Nov 10, 2010Estimated time for completion of this activity:
CNE: 1.0 hour
CPE: 1.0 hour
Target Audience
This activity is designed for internists, primary care physicians, family practitioners, endocrinologists, gynecologists, orthopedic surgeons, rheumatologists, nurses, and other clinicians involved in the care of patients with or at risk of developing osteoporosis and fractures.
Activity Goal
The goal of this CME/CE activity is to address gaps in competence and practice performance by:
- Stressing the importance of early screening and diagnosis of patients with or at risk for developing osteoporosis and fractures
- Identifying the pathways involved in the pathophysiology of osteoporosis and fractures
- Providing optimal strategies for prevention and treatment of osteoporosis based on updates on current and emerging therapies with regard to mechanism of action, efficacy, safety, and treatment regimen requirements for compliance
Learning Objective (s)
- Assess the mechanisms of action of approved and emerging osteoporosis agents, based on an understanding of bone remodeling and the pathophysiology of osteoporosis, in determining the role of these agents in preventing fractures and improving bone mineral density/bone quality in patients at risk of bone loss/fractures.
- Based on clinical efficacy and safety data, dosing regimens, and route of administration of approved osteoporosis agents, individualize fracture prevention and osteoporosis treatment regimens that improve bone health and facilitate compliance.
- Analyze the potential roles of emerging anabolic, antiresorptive, and dual-action therapies based on their safety and efficacy in preventing fractures/improving bone health when planning future regimens for use when these agents become available.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is an approved provider of continuing nursing education by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. PIK provider code: 080903-PROV.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
This activity is approved for 1.00 nursing contact hour(s).
DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This webcast is worth up to 1.0 contact hour (0.1 CEU). The ACPE Universal Activity Number assigned to this Application-type activity is 0052-0000-09-092-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
E. Michael Lewiecki, MD, FACP, FACE has received grant/research support from Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Procter & Gamble, Hoffmann-La Roche Inc, sanofi-aventis, and Wyeth; is on the speakers bureau of Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; is on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, Novartis Pharmaceuticals Corporation, Upsher-Smith Laboratories Inc, and Wyeth; is a direct stock shareholder with General Electric, Procter & Gamble, and Teva Pharmaceuticals; and is on the board of directors of International Society for Clinical Densitometry. Dr. Lewiecki will be discussing the off-label/investigational uses of bazedoxifene, denosumab, lasofoxifene, odanacatib, sclerostin monoclonal antibody, and strontium ranelate.
Paul D. Miller, MD has received grant/research support from Amgen Inc, Eli Lilly and Company, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis; and is a consultant for and/or on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, NPS Pharmaceuticals Inc, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis. Dr. Miller will be discussing the off-label/investigational uses of clodronate, etidronate, pamidronate, and strontium ranelate.
Dolores M. Shoback, MD is a consultant for Amgen Inc, and GlaxoSmithKline; and has received honoraria from GlaxoSmithKline and Kai Pharmaceuticals. Dr. Shoback will be discussing the off-label/investigational use of sclerostin monoclonal antibody.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Karen Gravelle, PhD has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
E. Michael Lewiecki, MD, FACP, FACE has received grant/research support from Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Procter & Gamble, Hoffmann-La Roche Inc, sanofi-aventis, and Wyeth; is on the speakers bureau of Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; is on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, Novartis Pharmaceuticals Corporation, Upsher-Smith Laboratories Inc, and Wyeth; is a direct stock shareholder with General Electric, Procter & Gamble, and Teva Pharmaceuticals; and is on the board of directors of International Society for Clinical Densitometry. Dr. Lewiecki will be discussing the off-label/investigational uses of bazedoxifene, denosumab, lasofoxifene, odanacatib, sclerostin monoclonal antibody, and strontium ranelate.
Paul D. Miller, MD has received grant/research support from Amgen Inc, Eli Lilly and Company, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis; and is a consultant for and/or on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, NPS Pharmaceuticals Inc, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis. Dr. Miller will be discussing the off-label/investigational uses of clodronate, etidronate, pamidronate, and strontium ranelate.
Dolores M. Shoback, MD is a consultant for Amgen Inc, and GlaxoSmithKline; and has received honoraria from GlaxoSmithKline and Kai Pharmaceuticals. Dr. Shoback will be discussing the off-label/investigational use of sclerostin monoclonal antibody.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Nov 10, 2009 Termination Date: Nov 10, 2010Nurses
Publish Date: Nov 10, 2009 Termination Date: Nov 10, 2010Pharmacists
Publish Date: Nov 10, 2009 Termination Date: Nov 10, 2010Estimated time for completion of this activity:
CNE: 1.0 hour
CPE: 1.0 hour
Target Audience
This activity is designed for internists, primary care physicians, family practitioners, endocrinologists, gynecologists, orthopedic surgeons, rheumatologists, nurses, and other clinicians involved in the care of patients with or at risk of developing osteoporosis and fractures.
Activity Goal
The goal of this CME/CE activity is to address gaps in competence and practice performance by:
- Stressing the importance of early screening and diagnosis of patients with or at risk for developing osteoporosis and fractures
- Identifying the pathways involved in the pathophysiology of osteoporosis and fractures
- Providing optimal strategies for prevention and treatment of osteoporosis based on updates on current and emerging therapies with regard to mechanism of action, efficacy, safety, and treatment regimen requirements for compliance
Learning Objective (s)
- Assess the mechanisms of action of approved and emerging osteoporosis agents, based on an understanding of bone remodeling and the pathophysiology of osteoporosis, in determining the role of these agents in preventing fractures and improving bone mineral density/bone quality in patients at risk of bone loss/fractures.
- Based on clinical efficacy and safety data, dosing regimens, and route of administration of approved osteoporosis agents, individualize fracture prevention and osteoporosis treatment regimens that improve bone health and facilitate compliance.
- Analyze the potential roles of emerging anabolic, antiresorptive, and dual-action therapies based on their safety and efficacy in preventing fractures/improving bone health when planning future regimens for use when these agents become available.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is an approved provider of continuing nursing education by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. PIK provider code: 080903-PROV.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
This activity is approved for 1.00 nursing contact hour(s).
DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This webcast is worth up to 1.0 contact hour (0.1 CEU). The ACPE Universal Activity Number assigned to this Application-type activity is 0052-0000-09-092-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
E. Michael Lewiecki, MD, FACP, FACE has received grant/research support from Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Procter & Gamble, Hoffmann-La Roche Inc, sanofi-aventis, and Wyeth; is on the speakers bureau of Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; is on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, Novartis Pharmaceuticals Corporation, Upsher-Smith Laboratories Inc, and Wyeth; is a direct stock shareholder with General Electric, Procter & Gamble, and Teva Pharmaceuticals; and is on the board of directors of International Society for Clinical Densitometry. Dr. Lewiecki will be discussing the off-label/investigational uses of bazedoxifene, denosumab, lasofoxifene, odanacatib, sclerostin monoclonal antibody, and strontium ranelate.
Paul D. Miller, MD has received grant/research support from Amgen Inc, Eli Lilly and Company, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis; and is a consultant for and/or on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, NPS Pharmaceuticals Inc, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis. Dr. Miller will be discussing the off-label/investigational uses of clodronate, etidronate, pamidronate, and strontium ranelate.
Dolores M. Shoback, MD is a consultant for Amgen Inc, and GlaxoSmithKline; and has received honoraria from GlaxoSmithKline and Kai Pharmaceuticals. Dr. Shoback will be discussing the off-label/investigational use of sclerostin monoclonal antibody.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Karen Gravelle, PhD has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
E. Michael Lewiecki, MD, FACP, FACE has received grant/research support from Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Procter & Gamble, Hoffmann-La Roche Inc, sanofi-aventis, and Wyeth; is on the speakers bureau of Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; is on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, Novartis Pharmaceuticals Corporation, Upsher-Smith Laboratories Inc, and Wyeth; is a direct stock shareholder with General Electric, Procter & Gamble, and Teva Pharmaceuticals; and is on the board of directors of International Society for Clinical Densitometry. Dr. Lewiecki will be discussing the off-label/investigational uses of bazedoxifene, denosumab, lasofoxifene, odanacatib, sclerostin monoclonal antibody, and strontium ranelate.
Paul D. Miller, MD has received grant/research support from Amgen Inc, Eli Lilly and Company, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis; and is a consultant for and/or on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, NPS Pharmaceuticals Inc, Procter & Gamble Pharmaceuticals, Roche Pharmaceuticals, and sanofi-aventis. Dr. Miller will be discussing the off-label/investigational uses of clodronate, etidronate, pamidronate, and strontium ranelate.
Dolores M. Shoback, MD is a consultant for Amgen Inc, and GlaxoSmithKline; and has received honoraria from GlaxoSmithKline and Kai Pharmaceuticals. Dr. Shoback will be discussing the off-label/investigational use of sclerostin monoclonal antibody.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Although current osteoporosis therapies are effective in reducing the risk of fracture and increasing bone mineral density, all have some issues that limit their use. The gastrointestinal side effects of oral bisphosphonates may preclude their use in some patients, while agents requiring intravenous or subcutaneous administration may pose problems with compliance for others. Recent advances in understanding bone remodeling and the pathophysiology of osteoporosis have led to the identification of novel therapeutic targets and the development of new emerging agents. In this program, three experts in the field – Dolores M. Shoback, MD, Paul D. Miller, MD, and E. Michael Lewiecki, MD – discuss these important advances and their implications for the treatment of patients at risk of fracture and bone loss.




